Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.45 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.45 |
| ▸ | PRKCZ | Q05513 | 3/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.41 |
| ▸ | CHUK | O15111 | 1/20 | 0.39 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.39 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.39 |
| ▸ | PIM1 | P11309 | 1/20 | 0.39 |
| ▸ | PRKACA | P17612 | 1/20 | 0.39 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.39 |
| ▸ | AKT1 | P31749 | 1/20 | 0.39 |
| ▸ | CLK2 | P49760 | 1/20 | 0.39 |
| ▸ | PRKX | P51817 | 1/20 | 0.39 |
| ▸ | PRKG2 | Q13237 | 1/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
| ▸ | PRKG1 | Q13976 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL357765 | 0.92 | IRAK4 (0.41) | CHRNB2CHRNA4IRAK4CHUKROCK1 | |
| SCHEMBL358623 | 0.80 | IRAK4 (0.41) | IRAK4 | |
| SCHEMBL359173 | 0.78 | IRAK4 (0.42) | IRAK4 | |
| Hydrochloric Acid SCHEMBL16146520 | 0.74 | IRAK4 (0.48) | CHRNB2CHRNA4PRKCZHTR1ASLC6A2 | |
| SCHEMBL359502 | 0.70 | PDGFRB (0.54) | — | |
| SCHEMBL3717239 | 0.69 | HTR1A (0.53) | CHRNB2CHRNA4PRKCZHTR1ASLC6A2 | |
| SCHEMBL5375637 | 0.69 | IKBKB (0.57) | CHRNB2CHRNA4PRKCZSLC6A2IRAK4 | |
| SCHEMBL3718465 | 0.69 | HTR1A (0.53) | CHRNB2CHRNA4PRKCZHTR1ASLC6A2 | |
| SCHEMBL1115666 | 0.69 | HTR1A (0.53) | CHRNB2CHRNA4PRKCZHTR1ASLC6A2 | |
| SCHEMBL12505399 | 0.68 | CHEK2 (0.42) | PRKCZPIM1ROCK1DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180298026-A1 | Pyrazolo[1,5a]Pyrimidine Derivatives as IRAK4 Modulators | HOFFMANN-LA ROCHE INC. | 2018-10-18 | — | — | US | claimed |
| US-10023589-B2 | Pyrazolo[1,5a]pyrimidine derivatives as IRAK4 modulators | HOFFMANN-LA ROCHE INC. (US) | 2018-07-17 | — | — | US | claimed |
| EP-3252054-A1 | PYRAZOLO[1,5A]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | F. Hoffmann-La Roche AG (CH) | 2017-12-06 | — | — | EP | claimed |
| US-20160207936-A1 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | HOFFMANN-LA ROCHE INC. | 2016-07-21 | — | — | US | claimed |
| US-20140303149-A1 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | HOFFMANN-LA ROCHE INC. (US) | 2014-10-09 | — | — | US | claimed |
| EP-2593457-A1 | PYRAZOLO [1, 5A]PYRIMIDINE AND THIENO [3, 2B]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-05-22 | — | — | EP | claimed |
| US-20120015962-A1 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | ARORA NIDHI (US) | 2012-01-19 | — | — | US | claimed |
| WO-2012007375-A1 | PYRAZOLO [1, 5A] PYRIMIDINE AND THIENO [3, 2B] PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-01-19 | — | — | WO | claimed |
| US-20180298026-A1 | Pyrazolo[1,5a]Pyrimidine Derivatives as IRAK4 Modulators | HOFFMANN-LA ROCHE INC. | 2018-10-18 | — | — | US | disclosed |
| US-10023589-B2 | Pyrazolo[1,5a]pyrimidine derivatives as IRAK4 modulators | HOFFMANN-LA ROCHE INC. (US) | 2018-07-17 | — | — | US | disclosed |
| EP-3252054-A1 | PYRAZOLO[1,5A]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | F. Hoffmann-La Roche AG (CH) | 2017-12-06 | — | — | EP | disclosed |
| US-20160207936-A1 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | HOFFMANN-LA ROCHE INC. | 2016-07-21 | — | — | US | disclosed |
| US-9255110-B2 | Pyrazolo[1,5a]pyrimidine derivatives as IRAK4 modulators | ROCHE PALO ALTO LLC (US) | 2016-02-09 | — | — | US | disclosed |
| US-20140303149-A1 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | HOFFMANN-LA ROCHE INC. (US) | 2014-10-09 | — | — | US | disclosed |
| EP-2593457-A1 | PYRAZOLO [1, 5A]PYRIMIDINE AND THIENO [3, 2B]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-05-22 | — | — | EP | disclosed |
| US-20120015962-A1 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | ARORA NIDHI (US) | 2012-01-19 | — | — | US | disclosed |
| WO-2012007375-A1 | PYRAZOLO [1, 5A] PYRIMIDINE AND THIENO [3, 2B] PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160207936-A1 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | IRAK4, IRAK1, IRAK2 | CHRNB2 3257/4885CHRNA4 1386/4885PRKCZ 2217/4885 |
| US-20140303149-A1 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | IRAK4, IRAK1, IRAK2 | CHRNB2 3257/4885CHRNA4 1386/4885PRKCZ 2217/4885 |
| US-10023589-B2 | Pyrazolo[1,5a]pyrimidine derivatives as IRAK4 modulators | IRAK4, IRAK1, IRAK2 | CHRNB2 3257/4885CHRNA4 1386/4885PRKCZ 2217/4885 |
| US-20120015962-A1 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | IRAK4, IRAK1, IRAK2 | CHRNB2 3257/4885CHRNA4 1386/4885PRKCZ 2217/4885 |
| US-20180298026-A1 | Pyrazolo[1,5a]Pyrimidine Derivatives as IRAK4 Modulators | IRAK4, IRAK1, IRAK2 | CHRNB2 3257/4885CHRNA4 1386/4885PRKCZ 2217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.